Stacie Lindsey: Compass Therapeutics completed enrollment of COMPANION-002

Stacie Lindsey, CEO at Cholangiocarcinoma Foundation, shared a post on LinkedIn:

“We are happy that our Industry Partner Compass Therapeutics completed enrollment of COMPANION-002, a Phase 2/3 clinical trial for patients with biliary tract cancers. This milestone for our partner is also a milestone for the CCF community. Thank you to all the patients who participated.”

Quoting Cholangiocarcinoma Foundation‘s post:

“Today, Compass Therapeutics completed enrollment of COMPANION-002, a Phase 2/3 clinical trial. A clinical research milestone for our partner is also a milestone for the CCF. A Thank You Message to patients who participated.”

Source: Stacie Lindsey/X and Cholangiocarcinoma Foundation/X